Loading...
OTC Markets
Totals
Securities
12,312
Dollar Vol
$1.9B
Share Vol
3.6B
Trades
359,836

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

PCSA
Processa Pharmaceuticals, Inc.

Common Stock

0.2143

-0.0119

-5.26%

Delayed (15 Min) Trade Data: 12:00am 07/14/2025

Processa Pharmaceuticals, Inc.

601 21st Street

Suite 300

Vero Beach, FL 32960

Business Description
Processa is an emerging pharmaceutical company focused on the clinical development of drug products that are intended to improve the survival and/or quality of life for patients who have a high unmet medical need. Our first drug, PCS-499, is an analog of an active metabolite of an already approved FDA drug. The advantage of PCS-499 is that it targets multiple pharmacological pathways which potentially may work in conditions caused by multiple pathophysiological changes. The lead indication currently under development for PCS-499 is Necrobiosis Lipoidica (NL). Patients with NL presently have no treatment options. PCS-499 has received orphan designation for NL and FDA has notified Processa that ...
More
Financial Reporting
Reporting Status
U.S. Reporting: SEC Reporting
Audited Financials
Audited
Latest Report
CIK
0001533743
Fiscal Year End
12/31
Company Officers & Contacts
David Young
CEO

Dr. Young has over 30 years of pharmaceutical research, drug development, and corporate experience. He is currenly the Chief Executive officer of Processa Pharmaceuticals, Inc. He was the Founder and is also the CEO of Promet Therapeutics, LLC, our largest shareholder. From 2009 to 2014 Dr. Young was the Chief Scientific Officer at Questcor where he obtained FDA approval and market exclusivity by completing the New Drug Application (NDA) process, working with FDA on modernizing the label, and leading all aspects of approval including the Advisory Committee Meeting that voted to approve the NDA for Infantile Spasms (IS), a deadly and debilitating very rare orphan indication. From 2006 to 2009, Dr. Young served as an independent Director for Questcor, During the eight years that Dr. Young was involved with Questcor, it transitioned to an orphan drug specialty pharmaceutical company, moving from an outdated Acthar label and near bankruptcy in 2007 to a modernized Acthar label that helped it to achieve sales greater than $750M per year and the ultimate sale of the Company for approximately $5.6 billion in 2014. Dr. Young received his B.S. in Physiology from the University of California at Berkeley, his M.S. in Medical Physics from the University of Wisconsin at Madison, and his Pharm.D. - Ph.D. with emphasis in Pharmacokinetics and Pharmaceutical Sciences from the University of Southern California.

James Stanker
CFO

Prior to joining the Company Mr. Stanker was providing financial consulting services to various companies, including Processa, and was an audit partner with Grant Thornton LLP from 2000 to 2016. Mr. Stanker has a Masters of Business Administration from California State University, East Bay and a Bachelor of Science from San Jose State University. He currently serves on the Board of Directors and is Chairman of the Audit Committee of GSE Systems, Inc. (NYSE MKT: GVP) and is a Certified Public Accountant.

Wendy Guy
Chief Admin. Officer

Ms. Guy has more than 20 years of experience in business operations. She has worked closely with Dr. Young over the last 18 years in corporate management and operations, HR, and finance. She was Co-Founder, Director, and Chief Administrative Officer of Promet Therapeutics, LLC. Prior to Promet, Ms. Guy was employed at Questcor Pharmaceuticals as Senior Manager, Business Operation in charge of the Maryland Office. During the time spent at Questcor, she built a dynamic administrative and contracts team, grew the Maryland Office from two employees to just under 100, and expanded the facility from 1,200 sq. ft. to 15,000 sq. ft. Prior to her position at Questcor, Ms. Guy was Senior Manager, U.S. Operations of AGI Therapeutics, plc. She has held senior level positions with the Strategic Drug Development Division of ICON, GloboMax, and Mercer Management Consulting. Ms. Guy received an A.A. from Mount Wachusett Community College.

Sian Bigora
Chief Development Officer

Dr. Bigora has over 20 years of pharmaceutical research, regulatory strategy and drug development experience working closely with Dr. Young. She was Co-Founder, Director, and Chief Development Officer at Promet Therapeutics, LLC. Prior to Promet, Dr. Bigora was Vice President of Regulatory Affairs at Questcor Pharmaceuticals (acquired by Mallinckrodt Pharmaceuticals in 2014) from 2009-2015, including leading efforts on modernizing the Acthar Gel label and in obtaining FDA approval in Infantile Spasms, events of material importance to Questcor’s subsequent success. Dr. Bigora's role at Questcor included heading up the development of a safety pharmacovigilance group and a clinical quality group. Prior to Questcor, Dr. Bigora was Vice President of Clinical and Regulatory Affairs, U.S. Operations of AGI Therapeutics, plc. Dr. Bigora received a Pharm.D. from the School of Pharmacy at the University of Maryland at Baltimore. She also completed a Fellowship in Pharmacokinetics and Pediatric Infectious Diseases at the University of Maryland at Baltimore.

Board of Directors
Patrick Lin

Mr. Lin has over 20 years of financing and investing experience in the Biopharm Sector. He was Co-Founder and Chairman of the Board of Promet Therapeutics, LLC. He is Founder and for more than past 15 years Managing Partner of Primarius Capital, a family office that manages public and private investments focused on small capitalization companies. For 10 years prior to forming Primarius Capital, Mr. Lin worked at several Wall Street banking and brokerage firms including Robertson Stephens & Co., E*Offering, and Goldman Sachs & Co. Mr. Lin was Co-Founding Partner of E*Offering. Mr. Lin received an MBA from Kellogg Graduate School of Management, a Master of Engineering Management, and a Bachelor of Science in Business Administration from the University of Southern California.

Geraldine Pannu
Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Ms. Pannu has over 25 years' experience in investment and financial management, fund operations, consulting and marketing. She is currently the Founding and Managing Partner of GLTJ Pioneer Capital that specializes in land acquisition, entitlement and vertical development of multifamily, student and senior housing in the San Francisco Bay Area. Previously, Ms. Pannu was the COO and Managing Partner for ChinaRock Capital Management, a leading hedge and venture capital fund company. She previously worked in McKinsey & Co, Monitor Company as management consultant. She had successfully raised capital for several hedge, venture capital and real estate funds. She also helped start-up companies to expand and diversify business categories, client verticals and grow revenue. Ms. Pannu was born in Shanghai and grew up in Hong Kong. She received her Bachelor of Business Administration degree from the Chinese University of Hong Kong and an MBA from Harvard Business School. She is fluent in English, Mandarin, Cantonese and Shanghainese.

Virgil Thompson
Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Virgil D. Thompson has been a director since June 1995 and was Chairman of the Board from January 2005 to June 2017. From July 2009 until July 2015, Mr. Thompson was Chief Executive Officer and a director of Spinnaker Biosciences, Inc., a privately held ophthalmic drug delivery company, and he is now its Chairman of the Board. From November 2002 until June 2007, Mr. Thompson served as President and Chief Executive Officer of Angstrom Pharmaceuticals, Inc., a privately held pharmaceutical company. From September 2000 to November 2002, Mr. Thompson was President, Chief Executive Officer and a director of Chimeric Therapies, Inc., a privately held biotechnology company. Mr. Thompson holds a B.S. in Pharmacy from Kansas University and a J.D. from The George Washington University Law School. We believe that Mr. Thompson possesses specific attributes that qualify him to serve as a member of our Board, including his experience as both an executive officer and director of publicly traded and private corporations in the pharmaceutical industry.

Justin Yorke
Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Mr. Yorke has over twenty-five years of experience in finance. Mr. Yorke joined San Gabriel Advisors, a private equity investment fund as a partner over 10 years ago. Mr. Yorke is involved in managing day-to-day activities of San Gabriel Advisors investment portfolios and is active on the boards of directors of the portfolios investments. Mr. Yorke is also currently a member of the board of directors of Splash Beverage, a private company. Prior to that, Mr. Yorke was based in Hong Kong where he acted as Fund Manager for Darier Henstch, a private Swiss Bank for over 10 years.

David Young
CEO

Dr. Young has over 30 years of pharmaceutical research, drug development, and corporate experience. He is currenly the Chief Executive officer of Processa Pharmaceuticals, Inc. He was the Founder and is also the CEO of Promet Therapeutics, LLC, our largest shareholder. From 2009 to 2014 Dr. Young was the Chief Scientific Officer at Questcor where he obtained FDA approval and market exclusivity by completing the New Drug Application (NDA) process, working with FDA on modernizing the label, and leading all aspects of approval including the Advisory Committee Meeting that voted to approve the NDA for Infantile Spasms (IS), a deadly and debilitating very rare orphan indication. From 2006 to 2009, Dr. Young served as an independent Director for Questcor, During the eight years that Dr. Young was involved with Questcor, it transitioned to an orphan drug specialty pharmaceutical company, moving from an outdated Acthar label and near bankruptcy in 2007 to a modernized Acthar label that helped it to achieve sales greater than $750M per year and the ultimate sale of the Company for approximately $5.6 billion in 2014. Dr. Young received his B.S. in Physiology from the University of California at Berkeley, his M.S. in Medical Physics from the University of Wisconsin at Madison, and his Pharm.D. - Ph.D. with emphasis in Pharmacokinetics and Pharmaceutical Sciences from the University of Southern California.

Other Company Insiders

Not available

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
BD & Company, Inc.

11155 Red Run Blvd

Suite 410

Owings Mills, MD 21117

Securities Counsel
Foley & Lardner LLP

One Independent Drive

Suite 1300

Jacksonville, FL 32202-5017

Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
DE, US, 2011
Employees
14 as of 12/26/2019
Shell
No
Products and Services

Not available

Company Facilities

Not available

Company Notes
Formerly=Heatwurx Inc. until 12-2017
Nasdaq
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.